Press release content from Globe Newswire. The AP news staff was not involved in its creation.
VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce .
Amarin Corporation plcMarch 17, 2021 GMT
28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk
Consistent reductions in overall stroke and in ischemic stroke observed across multiple subgroups
Administration of pure icosapent ethyl, VASCEPA, represents a novel clinical approach to stroke reduction
REDUCE-IT® STROKE abstract receives prestigious Paul Dudley White International Scholar Award to recognize the authors with the highest ranked abstract from the United States at the International Stroke Conference 2021
Share:
28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk
Consistent reductions in overall stroke and in ischemic stroke observed across multiple subgroups
Administration of pure icosapent ethyl, VASCEPA, represents a novel clinical approach to stroke reduction
REDUCE-IT® STROKE abstract receives prestigious Paul Dudley White International Scholar Award to recognize the authors with the highest ranked abstract from the United States at the International Stroke Conference 2021
DUBLIN, Ireland and BRIDGEWATER, N.J., March 17, 2021 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ:AMRN) today announced the presentation of REDUCE-IT® STROKE at the International Stroke Conference 2021, being held virtually from March 17 – March 19, 2021,
Triglyceride-lowering medication may lower stroke risk in people with heart disease
Taking the triglyceride-lowering medication icosapent ethyl cut the risk of stroke by an additional 36% in people at increased risk of cardiovascular disease who already have their bad cholesterol levels under control using statin medications, according to preliminary research to be presented at the American Stroke Association s International Stroke Conference 2021.
The virtual meeting is March 17-19, 2021 and is a world premier meeting for researchers and clinicians dedicated to the science of stroke and brain health.
Icosapent ethyl is a new way to further reduce the risk of stroke in patients with atherosclerosis or who are at high risk of stroke, who have elevated triglyceride levels and are already taking statins.
The two paired trials evaluated sotagliflozin, a drug that inhibits SGLT2 and SGLT1, according to a study published in <em>The New England Journal of Medicine</em>.
Intel Corporation (NASDAQ:INTC) Showing Off How Technology Will Change Fashion- Amarin Corporation (NASDAQ:AMRN) streetwisereport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetwisereport.com Daily Mail and Mail on Sunday newspapers.